NeuroMetrix to Exhibit at American Diabetes Association’s 73rd Scientific Sessions Will Feature the SENSUS Pain Management System Business Wire WALTHAM, Mass. -- June 10, 2013 NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported today that it will exhibit and participate in the American Diabetes Association’s (ADA) 73^rd Scientific Sessions. The ADA Scientific Sessions will be held on June 22-24 in Chicago at the McCormick Place Convention Center. NeuroMetrix will feature its first therapeutic product, the SENSUS^™ Pain Management System, which was launched during the first quarter of 2013. SENSUS is a transcutaneous electrical nerve stimulator intended for the symptomatic relief and management of chronic intractable pain. It is the only device designed specifically for people with diabetes and chronic pain. The most common cause of such pain in people with diabetes is painful diabetic neuropathy (PDN), which affects up to 5 million people in the US alone. Most patients with PDN have moderate to severe pain and half have sleep disturbances due to their pain. SENSUS offers physicians and their patients a non-narcotic pain relief option as a complement to medications. The device is lightweight, can be worn during the day, and may be used at bedtime before going to sleep. It is activated by the press of a single button. The Company will also conduct a meeting of its scientific advisory board consisting of international leaders in the detection, management, and treatment of the neurological complications of diabetes. Attendees are encouraged to visit NeuroMetrix at booth #947. About NeuroMetrix NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment of diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS^™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy and similar peripheral neuropathies. The company also markets the NC-stat^® DPNCheck^® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.neurometrix.com. Contact: NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief Financial Officer firstname.lastname@example.org
NeuroMetrix to Exhibit at American Diabetes Association’s 73rd Scientific Sessions
Press spacebar to pause and continue. Press esc to stop.